Emergent Biosolutions (EBS) Misses Q4 EPS by 1c; Issues Mixed Outlook
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.76 --0%
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $94.6 million versus the consensus estimate of $95.09 million.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
- TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
